Analysis of Fecal Metagenomics and Plasma Metabolomics Uncovers Alterations in Gut Microbiota and Plasma Metabolite Profiles in Rats Experiencing Diarrhea Induced by Abemaciclib - Top-Institutions - MDSpire

Analysis of Fecal Metagenomics and Plasma Metabolomics Uncovers Alterations in Gut Microbiota and Plasma Metabolite Profiles in Rats Experiencing Diarrhea Induced by Abemaciclib

  • By

  • Ling Ye

  • Li Cao

  • Qiong Du

  • Rui Xu

  • Yu Han

  • Jiyong Liu

  • January 19, 2026

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology
    • Gastroenterology
    • Microbiome Research

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology
    • Gastroenterology
    • Metabolomics

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology
    • Gastroenterology
    • Microbiome Research

  • #4

    Broad Institute of MIT and Harvard
    Broad Institute of MIT and Harvard

    Cambridge, MA

    Key Differentiators

    • Microbiome Research
    • Metabolomics
    • Cancer Biology

  • #5

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Oncology
    • Gastroenterology
    • Microbiome and Metabolomics

Original Source(s)

Analysis of Fecal Metagenomics and Plasma Metabolomics Uncovers Alterations in Gut Microbiota and Plasma Metabolite Profiles in Rats Experiencing Diarrhea Induced by Abemaciclib

  • by Ling Ye, Li Cao, Qiong Du, Rui Xu, Yu Han, Jiyong Liu

  • January 19, 2026

Related Content

Mammographic features differ with body composition in women with breast cancer

Quantitative assessment of background parenchymal enhancement is associated with lifetime breast cancer risk in screening MRI

The healthy participant effect: insights and results from a population-based case–control study on breast cancer